Publications are no longer accredited as of 21 September 2023.
AIM is known as the world’s most successful growth market and it has been focused on delivering funding to companies looking to fund their development and pursue their growth ambitions since well before the 2015 changes to EIS and VCT, the Brexit vote, the Patient Capital Review and the 2017 Autumn budget.
Marry this with a clear alignment with the Government’s growth-focused agenda for SMEs and scale-up and a strong performance in terms of returns and volatility in comparison to the main markets and you have a compelling case to take a more in-depth look at the sector.
We know that those advisers who have, have found AIM investments to be a useful conduit for BPR qualifying investments, in particular and our report looks at what they see in this market that is so renowned for its unpredictability in the most unpredictable of times.